---
title: "Pyridostigmine - Myasthenia Gravis"
sidebar: mydoc_sidebar
permalink: db00545-mesh-d009157-1.html
toc: false 
---


Path ID: `DB00545_MESH_D009157_1`
{% include image.html url="images/db00545-mesh-d009157-1.png" file="db00545-mesh-d009157-1.png" alt="db00545-mesh-d009157-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D011729">MESH:D011729 </a> | pyridostigmine | Drug |
| <a href="https://identifiers.org/UniProt:P22303">UniProt:P22303 </a> | Acetylcholinesterase | Protein |
| <a href="https://identifiers.org/GO:0001507">GO:0001507 </a> | acetylcholine catabolic process in synaptic cleft | BiologicalProcess |
| <a href="https://identifiers.org/HP:0011804">HP:0011804 </a> | Abnormal muscle physiology | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D009157">MESH:D009157 </a> | Myasthenia gravis | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Pyridostigmine | NEGATIVELY REGULATES | Acetylcholinesterase |
| Acetylcholinesterase | POSITIVELY REGULATES | Acetylcholine Catabolic Process In Synaptic Cleft |
| Acetylcholine Catabolic Process In Synaptic Cleft | AFFECTS RISK FOR | Abnormal Muscle Physiology |
| Abnormal Muscle Physiology | MANIFESTATION OF | Myasthenia Gravis |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00545#BE0000426](https://go.drugbank.com/drugs/DB00545#BE0000426)
  - [https://en.wikipedia.org/wiki/Pyridostigmine#Mechanism_of_action](https://en.wikipedia.org/wiki/Pyridostigmine#Mechanism_of_action)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1115/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1115/)
